Trial Profile
A Randomized Study Of The Safety And Efficacy Of Two Dose Schedules Of Gemcituzumab Ozogamicin In Patients With Intermediate-2 Or High-Risk Myelodysplastic Syndromes
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 24 Sep 2005 New trial record.